Memory prices are bruising profit margins, but CEO Paul Otellini says the chip giant can still thrive.

CEO Paul Otellini spent 2007 restoring investor faith in Intel; thanks to a slow economy and eroding memory prices, he's got more work to do. Image: Intel

Facing flagging profit margins and a skeptical Wall Street, Intel (INTC) CEO Paul Otellini hosted investors at the company's Silicon Valley headquarters Wednesday. His message: Despite a weak U.S. economy and an ugly memory market, the Internet boom will supercharge revenues at the world's largest chipmaker.

"We essentially think we can triple the market for our products," Otellini told a gathering of financial analysts. "And this isn't assuming that we have a full run of every market; it's assuming we have a moderate view of success."

But Intel's growth story is a tougher sell today than it was a few months ago, which helps explain why the company took the unusual step of hosting investors at its Santa Clara headquarters instead of doing the event in New York as usual. And the tough sell is not just an issue for Intel; since November, when it became clear that the U.S. subprime mortgage crisis could tip the economy into recession, the tech industry in general has been hit hard. Stocks like Intel and Apple (AAPL) that were investor darlings in 2007 have suffered gut-wrenching losses; Intel has shed more than $35 billion in market capitalization, a quarter of its value, since December. More

By Jon Fortt and Michal Lev-Ram

Will Apple give up some control over the iPhone in order to court corporate customers?

That’s one of the juiciest questions surrounding a gathering on Apple's (AAPL) campus Thursday, where CEO Steve Jobs has promised to open up the iPhone's software secrets to the world for the first time. Apple’s invitation to the event also hinted at new business-friendly features for the device, and Silicon Valley is abuzz about what that could mean. Will the BlackBerry-toting masses be able to trade in the company smartphone for an iPhone? More

Not much news was committed by Apple (AAPL) at its annual shareholders' meeting Tuesday in Cupertino — although the shareholders did manage to make headlines by passing a referendum (which the company opposed) that gives them a nonbinding say on executive compensation. "I'm hoping that the 'say on pay' proposal will help me with my $1 a year," Jobs quipped after the measure passed.

But as Piper Jaffray analyst Gene Munster points out in a report to clients Wednesday, Apple did clear up one nagging ambiguity: does the company's oft-stated goal of selling 10 million iPhones in 2008 mean that it hopes to sell 10 million phones within this calender year, or 10 million phones between June 29, 2007 and Dec. 31, 2008? It's a question often argued in heated words in the comment threads of Apple blogs (including this one). "We confirmed with Apple," writes Munster, "that the goal is to sell 10m iPhones 'in CY08' alone."

Munster goes on to say that, according to his models, Apple will easily beat that target. "We are currently modeling for 12.9m iPhones in CY08," he writes. "Exceeding the goal by 2.9m units or 29%."

To do that, Apple will have to expand the market for iPhones in Europe and Asia, something it has said it plans to do this year. COO Tim Cook was asked specifically about the huge mobile phone markets in China and India, where traffic in unlocked iPhones is reported to be heavy. "We will one day enter China," he said. "We're not saying when, and we will one day enter India."

For a particularly detailed account of the meeting, see AppleInsider here.

Fortune magazine investigative reporter Peter Elkind, who co-authored The Smartest Guys in the Room, the definitive account of the Enron meltdown, spent the better part of a year investigating Steve Jobs. He talked to more than 50 people who knew and worked with Jobs, including former Apple (AAPL) CEOs and current members of the board — nearly everybody, it seems, except Jobs, who refused to be interviewed for the piece.

The resulting article is the cover story of the current issue. It's a great read, with more fresh details about Jobs' life and management style than any profile I've ever read. Perhaps the most telling detail is the one laid out in the story's lead paragraphs:

In October 2003, as the computer world buzzed about what cool new gadget he would introduce next, Apple CEO Steve Jobs – then presiding over the most dramatic corporate turnaround in the history of Silicon Valley – found himself confronting a life-and-death decision.

During a routine abdominal scan, doctors had discovered a tumor growing in his pancreas. While a diagnosis of pancreatic cancer is often tantamount to a swiftly executed death sentence, a biopsy revealed that Jobs had a rare – and treatable – form of the disease. If the tumor were surgically removed, Jobs' prognosis would be promising: The vast majority of those who underwent the operation survived at least ten years.

Yet to the horror of the tiny circle of intimates in whom he'd confided, Jobs was considering not having the surgery at all. A Buddhist and vegetarian, the Apple CEO was skeptical of mainstream medicine. Jobs decided to employ alternative methods to treat his pancreatic cancer, hoping to avoid the operation through a special diet – a course of action that hasn't been disclosed until now.

For nine months Jobs pursued this approach, as Apple's board of directors and executive team secretly agonized over the situation – and whether the company needed to disclose anything about its CEO's health to investors. Jobs, after all, was widely viewed as Apple's irreplaceable leader, personally responsible for everything from the creation of the iPod to the selection of the chef in the company cafeteria. News of his illness, especially with an uncertain outcome, would surely send the company's stock reeling. The board decided to say nothing, after seeking advice on its obligations from two outside lawyers, who agreed it could remain silent.

In the end, Jobs had the surgery, on Saturday, July 31, 2004, at Stanford University Medical Center in Palo Alto, near his home. The revelation of his brush with death remained – like everything involving Jobs and Apple – a tightly controlled affair. In fact, nary a word got out until Jobs' tumor had been removed. The next day, in an upbeat e-mail to employees later released to the press, he announced that he had faced a life-threatening illness and was "cured." Jobs assured everyone that he'd be back on the job in September. When trading resumed a day after the announcement, Apple shares fell just 2.4%.

You can read the full story here, as well as an accompanying article about Apple, Inc. by Betsy Morris for which Jobs did agree to be interviewed. Both are highly recommended.

Disclosure: I'm an editor at Fortune and was interviewed by Elkind for his piece.